Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "intestinal peristalsis pathway" refers to the coordinated, wave-like muscular contractions of the intestinal wall that propel luminal contents through the gastrointestinal tract[5][7]. This process is regulated by the **enteric nervous system** (ENS), especially the myenteric plexus, in conjunction with smooth muscle cells, interstitial cells of Cajal (the pacemakers), and influenced by various neurotransmitters (such as acetylcholine, serotonin (5-HT), and substance P)[7][1]. Peristalsis is not a molecular entity but involves: - **Neurotransmitters**: including serotonin (5-HT, especially via 5-HT3 and 5-HT4 receptors), acetylcholine, and substance P[1][7]. - **Ion channels**: L-type calcium channels (essential for excitation-contraction coupling in smooth muscle)[7]. - **Receptors**: serotonin receptors (5-HT3, 5-HT4, among others), muscarinic acetylcholine receptors[7]. - **Other molecular components**: chloride channels involved in fluid transport (CFTR, Ca2+-activated Cl- channels), and Na+/K+ ATPase contribute to ionic gradients necessary for motility and secretion[1]. Key roles of the pathway include advancing intestinal contents, mixing chyme, and regulating nutrient absorption and bowel movements[5]. Dysregulation leads to human disease, such as chronic constipation and irritable bowel syndrome[1]. Macrophage-derived molecules like complement C1q have also been described as modulators of gut motility via interactions with enteric neurons[2]. Many drugs affect molecules within these pathways rather than the pathway as a whole. For example: - **5-HT4 receptor agonists** (e.g., prucalopride) enhance peristalsis by stimulating enteric neurons. - **Anticholinergics** inhibit peristalsis by blocking acetylcholine action. **Safety concerns** and biomarkers are defined only in the context of specific molecular targets (not the pathway itself). In summary: "Intestinal peristalsis pathway" is *not* a single, actionable molecular target but a descriptor for a complex, multi-component physiological process regulating gut motility[5][7]. Individual protein targets within this pathway can be considered drug targets, but the pathway as a whole is not a canonical molecular entity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intestinal peristalsis pathway.